Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
5.23
+0.01 (0.19%)
At close: Nov 20, 2024, 4:00 PM
5.31
+0.08 (1.53%)
Pre-market: Nov 21, 2024, 4:04 AM EST
Company Description
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases.
The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 384 |
| CEO | Joshua B. Cohen |
Contact Details
Address: 43 Thorndike Street Cambridge, Massachusetts 02141 United States | |
| Phone | 617 682 0917 |
| Website | amylyx.com |
Stock Details
| Ticker Symbol | AMLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001658551 |
| CUSIP Number | 03237H101 |
| ISIN Number | US03237H1014 |
| Employer ID | 46-4600503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Justin B. Klee | Co-Founder, Co-Chief Executive Officer and Director |
| Joshua B. Cohen | Co-Founder, Co-Chief Executive Officer and Director |
| James M. Frates M.B.A. | Chief Financial Officer |
| Dr. Camille L. Bedrosian M.D. | Chief Medical Officer |
| Tom Holmes | Chief Technical Operations Officer |
| Lindsey Allen | Head of Investor Relations and Communications |
| Shauna Horvath | Head of Global Marketing |
| Linda A. Arsenault | Chief Human Resources Officer |
| Chris Aiello | Head of Canada and GM |
| Keith White | Head of Global Market Access |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 17, 2024 | 8-K | Current Report |
| Aug 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 10, 2024 | 8-K | Current Report |